Kidney patients may not need long blood thinners after stents

NCT ID NCT04708587

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares taking two blood thinners (aspirin plus clopidogrel or prasugrel) for less than 3 months versus at least 6 months after a heart stent procedure in people with advanced chronic kidney disease. Researchers want to see if a shorter course reduces bleeding without increasing heart attacks or strokes. About 900 adults with severe kidney disease are being enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aspirin plus clopidogrel or prasugrel
What this could lead to: If it works, this could show that a shorter course of dual antiplatelet therapy is safer and just as effective for people with advanced kidney disease after stenting.
What could go wrong: This is a mid-sized trial, not a large Phase 3 study, so results may not apply to all patients. There is always a risk of bleeding or clotting events regardless of duration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES

Contacts and locations

Locations

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.